Contrasting Information Analysis (OTCMKTS:IAIC) & GoodRx (NASDAQ:GDRX)

GoodRx (NASDAQ:GDRX) and Information Analysis (OTCMKTS:IAIC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Insider and Institutional Ownership

63.8% of GoodRx shares are held by institutional investors. 5.9% of GoodRx shares are held by insiders. Comparatively, 23.8% of Information Analysis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

GoodRx has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Information Analysis has a beta of 3.25, indicating that its share price is 225% more volatile than the S&P 500.

Valuation & Earnings

This table compares GoodRx and Information Analysis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85 million	1.61	$30.44 million	$0.04	93.83
Information Analysis	$13.90 million	0.00	$410,000.00	$0.04	N/A

GoodRx has higher revenue and earnings than Information Analysis. Information Analysis is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for GoodRx and Information Analysis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3	6	4	0	2.08
Information Analysis	0	0	0	0	0.00

GoodRx currently has a consensus target price of $3.98, indicating a potential upside of 5.98%. Given GoodRx’s stronger consensus rating and higher probable upside, equities research analysts clearly believe GoodRx is more favorable than Information Analysis.

Profitability

This table compares GoodRx and Information Analysis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GoodRx	2.07%	7.22%	2.53%
Information Analysis	3.72%	18.48%	9.33%

Summary

GoodRx beats Information Analysis on 7 of the 13 factors compared between the two stocks.

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

About Information Analysis

Information Analysis, Inc. provides information technology services. The firm engages in the business of modernizing client information systems, developing and maintaining information technology systems, and performing consulting services to government and commercial organizations. It specializes in legacy systems modernization, ebusiness solutions, enterprise portals, system migration and re-hosting services, and enterprise application integration. The company was founded by Sandor Rosenberg in 1979 and is headquartered in Fairfax, VA.